We never know what demons other people are fighting, even if we think we see their problems from the outside. Those who ...

Eli Lilly leads incretins via Zepbound/Mounjaro, retatrutide at 28.7% loss, $50B R&D and US buildout, 2025 guidance, ...

Deep-brain recordings showed that Mounjaro and Zepbound briefly shut down the craving circuits linked to food noise in a ...

Tirzepatide, used in Mounjaro and Zepbound, can produce dramatic weight loss and improvements in blood pressure, cholesterol ...

Eli Lilly said on Thursday its next-generation obesity drug helped patients lose an average of 28.7% of their weight in a ...

Texas Attorney General Ken Paxton has filed a lawsuit against Eli Lilly and Co. (NYSE:LLY), accusing the pharmaceutical giant of bribing medical providers to promote its most profitable drugs, ...

A weight loss drug dubbed the "triple G" drug for its effectiveness in mimicking three hunger-regulating hormones showed promising results in new data released Thursday by its maker, Eli Lilly.

Eli Lilly's experimental drug, retatrutide, showed strong results in a late-stage trial, helping patients lose nearly 29% of ...

Retatrutide, the next generation of GLP-1 drug from Eli Lilly, helped participants lose an average of 71.2 pounds and reduce ...

Analysts were hoping for a safety profile similar to what was achieved in Phase II but an abnormal sense of touch, called ...

Eli Lilly will cut prices for its weight loss drug Zepbound, with single-dose vials now available for $299 per month through ...